Labcorp and ConcertAI announced a collaboration to optimize precision oncology research. The companies will work together to launch clinical studies in ways that minimize the burden on physician practices, drive faster patient recruitment, maximize patient retention, and ensure equitable access to research as a care option.
Through this collaboration, Labcorp will leverage ConcertAI’s suite of software-as-a-service (SaaS) offerings for clinical trial design, protocol optimization, site selection and study execution. These solutions, when paired with Labcorp’s expertise in clinical development services and diagnostic testing, will optimize oncology clinical trial design and execution using RWD and AI.
Clinical trials also increasingly require analysis of potential trial sites to identify and select locations containing patients with specific characteristics. Using data to help understand the availability of patients across a sampling of oncology cancer centers helps bring healthcare within reach for all and ensures that the design of a trial contains a diverse set of participants to measure drug safety and effectiveness in broadly representative populations. ConcertAI and Labcorp have structured a long-term collaboration to leverage data and analytics to find solutions to these difficult problems.
